Biolab creates AI that automates the analysis of pharmaceutical leaflets
From operational to strategic, the new tool turns time into value
Artificial intelligence developed by Biolab Farmacêutica to automate the comparison between the package leaflets of similar drugs and their respective reference drugs marks an unprecedented advance for the pharmaceutical sector. By transforming a traditionally manual process into an automated, precise and efficient task that meets Anvisa's requirements, the technology has been registered exclusively with the National Institute of Industrial Property (INPI) and is therefore legally protected until 2075.
The development of Artificial Intelligence involved the participation of the IT and Regulatory team to solve a challenge: the process of comparing a single package leaflet involved two people over 20 working days, which is equivalent to 32 hours of work. After many studies, the new tool accomplishes the same task with just one person in around 2 hours - a time saving of more than 90%.
"This technology eliminated an entirely operational bottleneck that was susceptible to human error. The time savings, combined with the accuracy of the data, made us decide to register it. In addition, its use frees up professionals for more strategic activities in line with Biolab's objectives," says Denise Queiroz, the company's Regulatory Affairs Director.
The AI combines the processing of the Gemini Flex engine with an agent programmed in Python, responsible for organizing and applying the prompts that carry out the analysis. The interface, built with Streamlit, is simple and intuitive: the user uploads two leaflets and, in a few minutes, the tool returns a table with all the points compared and any differences highlighted. The result can be exported as a PDF, facilitating documentation and internal processes.
"We developed an AI trained to focus specifically on regulatory items, such as composition, dosage, adverse effects, etc. The technology also accepts specific questions, such as identifying the presence of terms like 'drowsiness' or 'overdose' in the compared texts," adds Manuela Marques, Supply Chain and IT director.
About Biolab
Promoting a future with a better quality of life requires a tireless search for safe and innovative treatments. That's why Biolab, a Brazilian pharmaceutical company founded in 1997 and with an international presence, invests in research and partnerships to overcome the growing challenges of health.
With almost 4,000 employees and one of the largest sales forces in the country, the company stands out among Brazil's largest pharmaceutical companies. In 2025, it was recognized by LinkedIn Top Companies as one of the 15 best places to work in Brazil, based on criteria such as growth opportunities, skills development, diversity and stability.
Biolab operates in various specialties, such as dermatology, gynecology, orthopedics, gastroenterology, pediatrics, clinical medicine and the central nervous system, as well as being a leader in cardiology. The Biolab Genéricos, Avert Humana and Avert Biolab Saúde Animal business units contribute to a portfolio of more than 500 products.